Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
Background.Treatment options of recurrent malignant gliomas are very 7-Piece Power Reclining Sectional limited and with a poor survival benefit.The results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial.Patients and methods.The medical documentation of 19 adult patients with recurrent malignant gliomas